RxDoctor Payments Data

James Fuller, MD

Cardiovascular Disease · Greenwood, SCNPI 1689688301

Payments from drug & device makers

$4,450in general payments, 2019–2025

Across 238 payments — averaging $18.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$546
  • Amgen$527
  • Johnson & Johnson$387
  • Abbott$327
  • E.r. Squibb & Sons, L.L.C.$291
  • Boston Scientific$197
  • plus $2K from 35 others

What the payments were for

  • Food & beverage$4,450100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,450 in reported general payments places this provider in the 55th percentile of 257 cardiovascular disease providers in South Carolina.

See all cardiovascular disease providers in South Carolina

Medicare billing

Part B allowed, 2024
$146,546
Medicare patients
1,344
Services billed
2,674

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban268$225,197
EntrestoSacubitril/Valsartan171$167,286
Repatha SureclickEvolocumab76$49,242
XareltoRivaroxaban34$39,925
Metoprolol Succinate690$10,040
Ranolazine ErRanolazine29$4,463
Varenicline Tartrate12$3,476
Amlodipine Besylate437$3,069
Losartan Potassium182$2,782
Rosuvastatin Calcium196$2,549
Atorvastatin Calcium132$1,757
Potassium Chloride99$1,486
Valsartan33$1,353
Carvedilol169$1,341
Flecainide Acetate30$1,128

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$99$225,197268 claims
NovartisEntresto$546$167,286171 claims
Johnson & JohnsonXarelto$387$39,92534 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 257 cardiovascular disease providers in South Carolina.

Other cardiovascular disease in Greenwood

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →